Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease
(2017)
Journal Article
Batson, J., Toop, H. D., Redondo, C., Babaei-Jadidi, R., Chaikaud, A., Wearmouth, S. F., Gibbons, B., Allen, C., Tallant, C., Zhang, J., Du, C., Hancox, J. C., Hawtrey, T., Da Rocha, J., Griffith, R., Knapp, S., Bates, D. O., & Morris, J. C. (2017). Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease. ACS Chemical Biology, 12(3), 825-832. https://doi.org/10.1021/acschembio.6b01048
Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency and selectivi... Read More about Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease.